AbbVie
ABBV
282.68
-2.74
-0.96%
AbbVie
US · ABBV
#30 by market cap
Listed 1970
282.68
-2.74
-0.96%
Live - 5344 symbols - heartbeat 498s ago
· 2026-10-20 08:58
Analyst consensus 22 analysts
Buy
Avg price target 292.16 +3.4%
Price target rangecurrent 282.68
Low260.00
Avg292.16
High320.00
Buy 91%
Hold 9%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-09 | UBS | -- | Hold | 275.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 305.00 |
| 2026-10-08 | Cantor Fitzgerald | -- | Buy | 290.00 |
| 2026-10-08 | Piper Sandler | -- | Buy | 303.00 |
| 2026-10-08 | Guggenheim | -- | Buy | 288.00 |
| 2026-10-08 | J.P. Morgan | -- | Buy | 300.00 |
| 2026-10-07 | Morgan Stanley | -- | Buy | 310.00 |
| 2026-10-07 | Leerink Partners | -- | Buy | -- |
| 2026-10-06 | Scotiabank | -- | Buy | 320.00 |
| 2026-10-01 | BofA Securities | -- | Buy | 289.00 |
| 2026-10-01 | Scotiabank | -- | Buy | 280.00 |
| 2026-09-29 | BofA Securities | -- | Buy | 289.00 |
| 2026-09-29 | BMO Capital | -- | Buy | 300.00 |
| 2026-09-29 | RBC Capital | -- | Buy | 280.00 |
| 2026-09-28 | TD Cowen | -- | Buy | 280.00 |
| 2026-09-28 | CCORF | -- | Buy | 290.00 |
| 2026-09-28 | William Blair | -- | Buy | -- |
| 2026-09-25 | J.P. Morgan | -- | Buy | 285.00 |
| 2026-09-23 | Piper Sandler | -- | Buy | 303.00 |
| 2026-09-22 | Scotiabank | -- | Buy | 280.00 |
| 2026-09-21 | RBC Capital | -- | Buy | 280.00 |
| 2026-09-14 | RBC Capital | -- | Buy | 280.00 |
| 2026-09-11 | Scotiabank | -- | Buy | 280.00 |
| 2026-09-10 | Berenberg Bank | -- | Buy | 275.00 |
| 2026-09-10 | HSBC | -- | Buy | 315.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Improving
4 1
■ Upgrades■ Downgrades
- 4 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: BofA Securities moved from Hold to Buy on 2026-09-08.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-08 | BofA Securities | Hold → Buy | 282.00 |
| 2026-08-13 | Wolfe Research | Hold → Buy | 300.00 |
| 2026-08-05 | Erste Group | Hold → Buy | -- |
| 2026-07-16 | Citi | Buy → Hold | 260.00 |
| 2026-06-21 | Citi | Hold → Buy | 230.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-07-31 | -- | ±3.72% | -2.51% (in line) |
| 2026/Q1 | 2026-04-29 | -- | ±4.19% | +3.14% (in line) |
| 2025/Q4 | 2026-02-04 | -- | ±4.16% | -3.79% (in line) |
| 2025/Q3 | 2025-10-31 | -- | ±4.30% | -4.45% (beat) |
| 2025/Q2 | 2025-07-31 | -- | ±4.87% | -0.15% (in line) |
| 2025/Q1 | 2025-04-25 | -- | ±5.89% | +3.15% (in line) |
| 2024/Q4 | 2025-01-31 | -- | ±5.36% | +4.70% (in line) |
| 2024/Q3 | 2024-10-30 | -- | ±4.00% | +6.36% (beat) |
| 2024/Q2 | 2024-07-25 | -- | ±4.23% | +3.38% (in line) |
| 2024/Q1 | 2024-04-26 | -- | ±4.94% | -4.58% (in line) |
| 2023/Q4 | 2024-02-02 | -- | ±3.97% | +0.64% (in line) |
| 2023/Q3 | 2023-10-27 | -- | ±4.64% | -4.32% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-20 08:58:55 · For reference only, not investment advice and not tailored to your situation.
patent cliff fears priced in years ago and the new drugs stepped up more than skeptics expected. dividend yield here is still doing a lot of the work for the stock.